Case Report: IGFBP5-ALK fusion-positive case of high-grade endometrial stromal sarcoma with response to ALK-targeted therapy
This case highlights the first documented response to an ALK inhibitor in <i>ALK</i>-rearranged HG-ESS. The findings underscore the importance of comprehensive molecular profiling in identifying targetable alterations in rare sarcomas and support the use of iruplinalkib as an effective therapeutic option in this setting.
Authors
- Yu Cheng (ORCID: https://orcid.org/0000-0003-3388-5485)
- Jinkun Wu
- Weiwei Zhang
- Shujie Song
Institutions
- Yuhuangding Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.3389/fonc.2025.1720854
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shandong Province